Earnings Call · Q4 FY2023·2024-03-11

Q4 23EPS +100.00%*·Rev n/aQ3 23EPS +100.00%*·Rev n/aQ2 23EPS +90.00%·Rev n/aQ1 23EPS +54.55%·Rev n/a⚠ consensus missing

CytomX Therapeutics, Inc. CTMX

Chris Ogden — Chief Financial Officer

Sean McCarthy — Chief Executive Officer

−14.3%1d on move date−15.4% vs SPY3d−17.9%5d−19.5%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more CTMX calls or request research access.

More CTMX calls Browse calls Request research access